Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Health Ministry Approves 28 Products including Oblean, Kadcyla
September 26, 2013
- Discussions on Reform of the High-cost Healthcare Benefit System on the Horizon; Will It Be Possible to Reduce Drug Copayments?
September 25, 2013
- Japan Needs Generic Drug Makers that Can Compete in the Global Market: Director Jo of EAD
September 25, 2013
- Regulatory Reform Council Sets Out Policies to Monitor Ministries’ Deregulation Efforts
September 24, 2013
- MHLW to Introduce E2B (R3) Format in April 2016
September 24, 2013
- FTC’s Legal Intervention in Diovan Issue Possible, but Only with New Facts: Lawyer
September 20, 2013
- MHLW Requests Revision of Package Inserts for Losartan, Celecoxib, 9 Other Drugs
September 19, 2013
- MHLW Plans to Establish Ethics Committee Certification System to Improve the Quality of Clinical Research
September 18, 2013
- Diovan Scandal Undermined National Interests, Health Ministry Official Says
September 18, 2013
- Director Jo of EAD Urges Drug Makers to Go on the Offensive
September 18, 2013
- PAFSC Second Committee Supports Hepatitis C Treatment Simeprevir, Plasma Fraction Product Hizentra
September 17, 2013
- Intussusception to Be Added to Adverse Reaction Section of Package Insert of RotaTeq
September 17, 2013
- Regulatory Reform Council Puts Off Concluding Discussion on Use of Clinical Intervention Study Data for Drug Applications
September 13, 2013
- Ms Ishii of LDP Calls for Permanent Extension of R&D Tax Credit for High-Level Investment
September 13, 2013
- MHLW Lifts Certified Oncologist Requirement for Tarceva
September 12, 2013
- Medical Expenditure for Dispensing Totaled 6,590.2 Billion Yen in FY2012; Generic Drug Ratio 28.7%
September 12, 2013
- Diovan Panel Poised to Conduct Hearings with Ex-Novartis Employee, Authors
September 11, 2013
- Education Ministry Requests 950 Million Yen Budget for Promoting Generic Use at National University Hospitals
September 11, 2013
- PMDA Eyes Mandatory Electronic Filings for NDA Clinical Trial Data from FY2016
September 11, 2013
- Cabinet Secretariat’s TPP Headquarters Briefs Industry Organizations on 19th Round of TPP Talks
September 11, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…